Tenex, Intuniv(guanfacine)
Intuniv (guanfacine) is a small molecule pharmaceutical. Guanfacine was first approved as Tenex on 1986-10-27. It is used to treat attention deficit disorder with hyperactivity and hypertension in the USA. It has been approved in Europe to treat attention deficit disorder with hyperactivity. It is known to target alpha-2B adrenergic receptor, alpha-2C adrenergic receptor, and alpha-2A adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Intuniv (generic drugs available since 1995-10-17, discontinued: Tenex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Guanfacine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INTUNIV | Takeda | N-022037 RX | 2009-09-02 | 4 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| guanfacine | ANDA | 2023-06-14 |
| intuniv | New Drug Application | 2021-01-26 |
| tenex | New Drug Application | 2013-05-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| hypertension | EFO_0000537 | D006973 | I10 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
71 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 2 | 7 | 11 | 5 | 25 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | 1 | — | 2 | |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | — | 2 | — | 2 |
| Schizotypal personality disorder | D012569 | F21 | — | 1 | — | 1 | — | 2 | |
| Chronic pain | D059350 | HP_0012532 | — | — | — | 1 | 1 | 2 | |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | — | 1 | 1 | — | 2 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | — | — | 1 | 1 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | — | 1 |
| Psychotic disorders | D011618 | F20.81 | — | — | — | 1 | — | 1 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | — | 1 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | 2 | — | — | 3 |
| Delirium | D003693 | R41.0 | — | 1 | 1 | — | — | 2 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Smoking cessation | D016540 | EFO_0004319 | — | 2 | — | — | — | 2 | |
| Smoking | D012907 | EFO_0003768 | F17 | — | 2 | — | — | — | 2 |
| Cocaine-related disorders | D019970 | F14 | 1 | 1 | — | — | — | 2 | |
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | — | 1 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | 1 | — | — | — | 1 |
| Alcohol abstinence | D064829 | 1 | 1 | — | — | — | 1 | ||
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | — | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | — | — | — | 1 |
| Separation anxiety | D001010 | EFO_1001916 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | — | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bursitis | D002062 | EFO_1000941 | M71.9 | — | — | — | — | 1 | 1 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | — | — | 1 | 1 | |
| Postoperative pain | D010149 | G89.18 | — | — | — | — | 1 | 1 | |
| Cognitive aging | D000066492 | — | — | — | — | 1 | 1 | ||
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | — | — | 1 | 1 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GUANFACINE |
| INN | guanfacine |
| Description | Guanfacine is a member of acetamides. |
| Classification | Small molecule |
| Drug class | antihypertensives (guanidine deriviatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NC(=O)Cc1c(Cl)cccc1Cl |
Identifiers
| PDB | — |
| CAS-ID | 29110-47-2 |
| RxCUI | 40114 |
| ChEMBL ID | CHEMBL862 |
| ChEBI ID | 5558 |
| PubChem CID | 3519 |
| DrugBank | DB01018 |
| UNII ID | 30OMY4G3MK (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRA2B
ADRA2B
ADRA2C
ADRA2C
ADRA2A
ADRA2A
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Variants
Clinical Variant
No data
Financial
Intuniv - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,836 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,397 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more